Who Paid My Doc
Malik Kahook
Glaucoma Specialist Aurora, CO Medical Doctor
NPI 1578537122 CMS profile 891642
12605 E 16Th Ave, Aurora, CO 80045
General payments
$1,343,570
Research payments
$0
Ownership & investment interest
$2,293,879
Research they led as principal investigator
$28,308
Through program year 2025, Malik Kahook of Aurora, CO is reported in the CMS Open Payments database as having received $1,343,570 across 134 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $28,308 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $2,293,879 across 10 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Glaucoma Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $464 | 6 | |
| 2024 | General | $615 | 7 | |
| 2023 | General | $714 | 12 | |
| 2022 | General | $571,892 | 23 | |
| 2021 | General | $258,750 | 5 | |
| 2020 | General | $244,083 | 24 | |
| 2019 | General | $267,051 | 57 | |
| 2025 | Ownership | $1,050,970 | 8 | |
| 2024 | Ownership | $792,872 | 1 | |
| 2023 | Ownership | $450,036 | 1 |
Beside peers
- Malik Kahook
- Glaucoma Specialist median
- Middle half of Glaucoma Specialist
- National median
In program year 2025, general payments to Malik Kahook were reported at $464. Among 370 Glaucoma Specialist profiles paid that year, the median was $597 and the middle half received between $244 and $1,607.
Show as a table
| Year | Malik Kahook | Glaucoma Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $267,051 | $433 | $150–$1,170 | $163 |
| 2020 | $244,083 | $242 | $74–$693 | $114 |
| 2021 | $258,750 | $324 | $122–$936 | $132 |
| 2022 | $571,892 | $399 | $121–$1,081 | $149 |
| 2023 | $714 | $458 | $190–$1,208 | $160 |
| 2024 | $615 | $558 | $215–$1,359 | $164 |
| 2025 | $464 | $597 | $244–$1,607 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
526
Drug cost
$58,966
Branded share of claims
37.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lumigan Bimatoprost | Brand | 47 | $30,114 | |
| Simbrinza Brinzolamide/Brimonidine Tart | Brand | 43 | $14,487 | |
| Latanoprost | Generic | 206 | $3,519 | |
| Combigan Brimonidine Tartrate/Timolol | Brand | 11 | $3,284 | |
| Alphagan P Brimonidine Tartrate | Brand | 13 | $2,368 | |
| Brimonidine Tartrate | Generic | 54 | $1,877 | |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | Brand | 82 | $1,700 | |
| Dorzolamide Hcl | Generic | 49 | $1,407 | |
| Timolol Maleate | Generic | 21 | $212 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$29,747
Medicare patients
185
Services billed
765
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 57% | |
| Diabetes | 27% | |
| Ischemic heart disease | 27% | |
| Chronic kidney disease | 24% | |
| Osteoporosis | 21% | |
| Cancer | 19% | |
| Atrial fibrillation | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
134 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Glaucoma Specialist in Colorado
Leonard Seibold
Glaucoma Specialist · Aurora, CO
Stephanie Muylaert
Glaucoma Specialist · Littleton, CO
Monica Ertel
Glaucoma Specialist · Aurora, CO
Micah Rothstein
Glaucoma Specialist · Longmont, CO
Jeffrey Soohoo
Glaucoma Specialist · Aurora, CO
Kent Bashford
Glaucoma Specialist · Fort Collins, CO
Related records
Glaucoma Specialist in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Glaucoma Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.